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Abstract
Background: Neprilysin has an essential role in regulating fluid balance and vascular resistance, and neprilysin
inhibitors have shown beneficial effects in patients with heart failure. However, the potential predictive value of
neprilysin levels as a biomarker for cardiovascular risk remains unclear. The aim of this study was to assess the
prognostic value of soluble neprilysin (sNEP) levels in patients with ischemic heart disease.
Methods: Neprilysin levels were measured in 694 consecutive patients with coronary artery disease (CAD)
undergoing percutaneous coronary intervention (PCI). These patients were classified into two groups according to
their serum levels of neprilysin and categorized into the lower neprilysin group (n = 348) and the higher neprilysin
group (n = 346). The primary clinical endpoint was all-cause mortality, and the secondary endpoint was a composite
of major adverse cardiac events (MACE).
Results: The median sNEP level was 76.0 pg/ml. The median sNEP levels were higher in patients with left
ventricular ejection fraction (LVEF) ≥40% (77.6 pg/ml, interquartile range 46.6–141.3) than in those with LVEF < 40%
(70.0 pg/ml, interquartile range 47.1–100.6; P = 0.032). Among all patients, each clinical outcome and MACE did not
differ significantly according to the groups divided into median, tertile, or quartile of sNEP levels during a median
follow-up of 28.4 months. We did not find a significant relationship between sNEP levels and clinical outcomes in
multivariate Cox regression analysis. Among patients with LVEF < 40%, an increased sNEP level was associated with
a higher rate of all-cause death (adjusted hazard ratio 2.630, 95% confidence interval 1.049–6.595, P = 0.039).
Conclusion: Serum sNEP levels are not associated with long-term mortality or cardiovascular outcomes after PCI in
patients with CAD. In the LVEF < 40% group, increased sNEP levels may be associated with a higher risk of all-cause
death.
Keywords: Neprilysin, Coronary artery disease, Percutaneous coronary intervention, Prognosis, Left ventricular
ejection fraction
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Background
Neprilysin (NEP) is a zinc-dependent type II integral
membrane peptidase that degrades a variety of vasoactive peptides such as atrial natriuretic peptide, brain or
B-type natriuretic peptide, bradykinin, adrenomedullin,
and endothelin-1 [1–3]. These vasoactive peptides play
essential roles in fluid balance and vascular resistance
[4–6]. Therefore, efforts have been made to inhibit
neprilysin as a treatment target for heart failure (HF),
and recent clinical trials have obtained remarkable results. Combined inhibition of NEP and angiotensin have
been established the effective therapeutic value in patients with HF and reduced ejection fraction (HFrEF) or
acute HF [7–9].
Circulating NEP levels were significantly associated
with cardiovascular death or HF hospitalization in patients with HFrEF [10]. In addition, previous studies
identified a positive association in acute HF [11, 12],
whereas other studies did not confirm an association
of soluble NEP (sNEP) and cardiovascular mortality
and morbidity in patients with HF and preserved ejection fraction (HFpEF) and ST-segment elevation myocardial infarction [13, 14]. The impact of sNEP levels
on clinical outcomes in patients with ischemic heart
disease has not been well established. Therefore, the
present study aimed to demonstrate the association
between serum sNEP levels and mortality and cardiovascular events in patients with coronary artery disease (CAD) undergoing percutaneous coronary
intervention (PCI).
Methods
Study population

Between September 2015 and Novermber 2017, 796 patients with CAD scheduled for PCI and older than 20
years were screened. Exclusion criteria were as follows:
patients with cardiogenic shock, patients with end-stage
renal disease and on dialysis, patients who managed conservative care without coronary intervention, and patients without sufficient blood samples. Of the 796
eligible patients, 694 had samples available for measurement of serum levels of neprilysin. All participants provided written informed consent to participate before PCI
and blood sampling. The study protocol was reviewed
and approved by the appropriate institutional review
board.
PCI was performed according to standard techniques
and left to the operators’ discretion. After the procedure,
all patients were recommended to receive optimal
pharmacological therapy, including dual-antiplatelets,
statins, beta-blockers, or renin-angiotensin blockade, if
indicated, following standard European and American
guidelines [15–18]. Clinical follow-up was performed
every 3 months after the index procedure.
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Laboratory measurement

Blood was drawn upon arrival at the catheterization laboratory and was collected immediately after sheath insertion and before the PCI. After the blood was
centrifuged, plasma was subsequently stored at − 80 °C.
Serum sNEP levels were measured by an optimized
enzyme-linked immunosorbent assay (ELISA) using a
High-Sensitivity Soluble Neprilysin (Human) ELISA Kit
(Aviscera Bioscience, INC., Santa Clara, CA, USA). The
measurement of neprilysin levels was performed in the
Clinical Research Laboratory, Incheon St. Mary’s Hospital, The Catholic University of Korea.
Study endpoints and definitions

The primary endpoint was all-cause death. The secondary endpoint was major adverse cardiovascular events
(MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, any revascularization,
and hospitalization for HF. Patient follow-up data, including censored survival data, were collected through
March 31, 2019, via hospital chart review, telephone interviews with patients by trained reviewers who were
blinded to the study results, and reviews of the database
of the National Health Insurance Corporation, Korea,
using a unique personal identification number.
Myocardial infarction was defined as an elevation of a
cardiac enzyme level, especially high-sensitivity troponin
T, above the upper limit with ischemic symptoms or
electrocardiographic findings indicative of ischemia that
was not related to the PCI. Stroke was defined as any
nonconvulsive focal or global neurological deficit of
abrupt onset lasting more than 24 h caused by ischemia
or hemorrhage within the brain. Revascularization was
defined as any repeat PCI which was unexpected and
clinically indicated revascularization. Planed and staged
interventions were not considered as repeat revascularization. All events were adjudicated by two interventional
cardiologists.
Statistical analysis

Continuous variables are expressed as the mean ± standard deviation or median (interquartile range (IQR)) and
were analyzed by independent sample t-test or the
Mann-Whitney U-test according to the distribution.
Categorical variables are presented as percentages or
rates and were analyzed by the chi-square test or Fisher’s
exact test. A comparison of clinical outcomes between
groups was performed with the long-rank test. Receiver
operating characteristic (ROC) curve analyses were performed to identify the optimal cutoff value of neprilysin
associated with clinical outcomes. Kaplan-Meier curves
were used to analyze the overall survival rate and adverse events of patients. Cox proportional hazard models
were applied to analyze the hazard ratio (HR) and 95%
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confidence interval (CI) for clinical outcomes. We examined the association between sNEP levels on a continuous scale and all-cause mortality or adverse
cardiovascular events during the follow-up period using
the Cox proportional hazard model. All analyses were 2tailed, and P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS
20.0 statistical software (SPSS Inc., Chicago, IL, USA)
and R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results
Study population and characteristics

The mean age of all available 694 patients was 65.9 ±
11.9 years old, and 67.0% of the patients were men.
Among them, 48.0% were diagnosed with myocardial infarction. The mean left ventricular ejection fraction
(LVEF) was 55.0 ± 11.7%, and LVEF < 40% was observed
in 86 (12.4%) patients. The median serum neprilysin
level was 76.0 pg/ml (IQR 46.8 to 133.9). Table 1 presents the baseline characteristics according to the groups
divided by the median neprilysin level. The age of the
neprilysin ≤76.0 pg/ml group was significantly younger
than that of the neprilysin > 76.0 pg/ml group. The
prevalence of a family history of CAD was higher in the
high neprilysin level group. LVEF was not different between groups. Laboratory and procedural data were also
similar between the two groups.
The median sNEP levels were higher in patients with
LVEF ≥40% (77.6 pg/ml, IQR 46.6 to 141.3) than in
those with LVEF < 40% (70.0 pg/ml, IQR 47.1 to 100.6;
p = 0.032), whereas the median sNEP levels did not differ
according to current smoking status, all-cause mortality,
or MACE (Fig. 1).
Clinical outcomes

The median follow-up duration was 28.4 months (IQR
23.4 to 36.2). During the overall follow-up, the incidences of all-cause death and MACE were 6.9 and 6.2%,
respectively. The clinical outcomes are presented in
Table 2. Among all patients, each clinical outcome and
MACE did not differ significantly between the two
groups. ROC curve analysis showed that the area under
the curve for all-cause death and MACE were 0.547
(95% CI 0.509–0.584, P = 0.289) and 0.542 (95% CI
0.504–0.579, P = 0.368), respectively (Fig. 2). Figure 3
shows the Kaplan-Meier curves for all-cause death and
MACE up to 28.4 months in all patients. When neprilysin was divided into tertiles and quartiles, there were no
significant differences in all-cause death or MACE between groups (Table 3). Multivariate Cox regression
analysis using various models demonstrated that the
higher neprilysin group was not consistently associated
with all-cause death or MACE (Table 4). Univariate and
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multivariate analyses showed that the neprilysin > 76.0
pg/ml group was not a predictor of all-cause death (HR
1.558, 95% CI 0.848–2.863, P = 0.153) (Table 5) or
MACE (HR 1.450, 95% CI 0.785–2.679, P = 0.235).
Subgroup analysis

We stratified the overall patients by age, sex, and important comorbidities. This subgroup analysis revealed
consistent trends irrespective of each subgroup except
the LVEF < 40% group (Fig. 4). The LVEF < 40% group
had a trend of a higher rate of all-cause death in the
neprilysin > 76.0 pg/ml group without a statistically significant interaction (HR 2.630, 95% CI 1.049–6.595, P
for interaction = 0.150) and a marginal trend of a higher
rate of MACE (HR 3.213, 95% CI 0.989–10.441, P for
interaction = 0.083). In the analysis for an association between sNEP levels in continuous scales and relative hazard for outcomes, the Cox proportional hazard model
results suggest that sNEP level is not a significant factor
by itself when considered without its interaction with
LVEF (P = 0.094). However, the detailed analysis indicates that increased sNEP levels are associated with a
higher risk of all-cause death and cardiovascular adverse
events for patients with decreased LVEF but not for
those with preserved LVEF (P for interaction = 0.003 for
all-cause mortality, P for interaction = 0.004 for MACE)
(Fig. 5).

Discussion
The current study found that serum sNEP levels are not
associated with mortality or cardiovascular outcomes
during follow-up. However, increased sNEP levels tend
to be associated with a higher risk of all-cause mortality
or cardiovascular events in patients with reduced LVEF
but not in patients with preserved LVEF.
There are 3 types of natriuretic peptides, atrial, brain
or B-type, and C-type [19–22]. Natriuretic peptides have
potent effects on sodium and fluid balance, and they
have a very important role in various heart diseases [1,
23, 24]. Circulating natriuretic peptides are cleared
through 2 essential mechanisms: one is natriuretic peptide receptor-mediated clearance, and the other is degradation by enzymes. NEP is one of the most important
proteases that cleaves human natriuretic peptides, and
the cleavage sites on natriuretic peptides have been well
established [1, 25]. NEP was isolated for the first time in
the 1970s as an endopeptidase in renal proximal tubule
cells of rabbits [26, 27]. Since then, several brilliant studies have established the function of NEP. NEP is not
only a potent hydrolyzer of natriuretic peptides but also
a membrane-bound enzyme that degrades a large number of vasodilator peptides, including adrenomedullin,
bradykinin, angiotensin, substance P, endothelin-1, and
amyloid-beta protein [1, 28–31]. Although NEP is a
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Table 1 Baseline clinical and angiographic characteristics
Variables

Neprilysin
≤76.0 pg/ml
(n = 348)

Neprilysin
> 76.0 pg/ml
(n = 346)

P value

Age (years)

66.8 ± 11.2

64.9 ± 12.4

0.027

Male

231 (66.4%)

234 (67.6%)

0.394

Body mass index (Kg/m2)

24.5 ± 4.1

24.5 ± 4.1

0.983

Hypertension

238 (68.4%)

249 (72.0%)

0.172

Diabetes mellitus

138 (39.7%)

124 (35.8%)

0.169

Dyslipidemia

123 (35.9%)

120 (35.4%)

0.482

Smoking

90 (25.9%)

110 (31.8%)

0.050

Family history of coronary artery disease

20 (5.7%)

33 (9.5%)

0.041

Chronic kidney disease

16 (4.6%)

17 (4.9%)

0.493

Prior stroke

37 (10.6%)

37 (10.7%)

0.538

Prior myocardial infarction

32 (9.2%)

23 (6.6%)

0.135

Prior percutaneous coronary intervention

46 (13.2%)

43 (12.4%)

Clinical presentation
Stable angina

19 (5.5%)

22 (6.4%)

Unstable angina

153 (44.0%)

155 (44.8%)

NSTEMI

110 (31.6%)

107 (30.9%)

STEMI

60 (17.2%)

56 (16.2%)

Silent myocardial ischemia

6 (1.7%)

6 (1.7%)

54.5 ± 12.1

55.6 ± 11.3

Left ventricular ejection fraction (%)

0.422
0.982

0.222

Total cholesterol (mg/dl)

165.6 ± 46.3

164.2 ± 43.2

0.676

Triglyceride (mg/dl)

141.0 ± 86.0

154.1 ± 133.4

0.137

HDL cholesterol (mg/dl)

41.6 ± 10.5

41.3 ± 9.9

0.682

LDL cholesterol (mg/dl)

101.0 ± 34.1

99.0 ± 31.8

0.415

High-sensitivity C-reactive protein (mg/l)

8.4 ± 23.9

10.0 ± 28.0

0.406

eGFR (ml/min/1.73m2)

69.6 ± 26.4

73.8 ± 30.8

0.056

NT-proBNP (pg/ml)

1384.0 ± 4585.9

1919.1 ± 6243.0

0.199

Culprit lesion

0.628

Left anterior descending

171 (51.5%)

165 (49.8%)

Left circumflex

62 (18.7%)

54 (16.3%)

Right coronary artery

83 (25.0%)

95 (28.7%)

Left main

15 (4.5%)

17 (5.1%)

1-vessel disease

164 (49.4%)

146 (44.1%)

2-vessel disease

100 (30.1%)

119 (36.0%)

3-vessel disease

68 (20.5%)

66 (19.9%)

Multivessel disease

103 (29.6%)

112 (32.4%)

0.240

Number of total stents

1.6 ± 1.0

1.7 ± 1.2

0.139

Extent of coronary artery disease

0.256

Mean diameter of stents

3.10 ± 0.43

3.11 ± 0.41

0.677

Total length of stents

42.2 ± 28.8

46.8 ± 35.4

0.065

eGFR indicates estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, NSTEMI non-ST-segment elevation myocardial
infarction, NT-proBNP N-terminal pro-B-type natriuretic peptide, STEMI ST-segment elevation myocardial infarction
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Fig. 1 Comparison of soluble neprilysin levels. a Left ventricular ejection fraction (b) smoking (c) all-cause death (d) major adverse
cardiovascular events

Table 2 Clinical outcomes according to the soluble neprilysin
level
Outcome

Neprilysin

Log
rank,
≤76.0 pg/ml > 76.0 pg/ml
P
(n = 348)
(n = 346)
value

All-cause death

20 (5.7%)

28 (8.1%)

0.213

Cardiovascular death

10 (2.9%)

15 (4.3%)

0.292

Nonfatal myocardial infarction

0 (0%)

1 (0.3%)

0.316

Nonfatal stroke

2 (0.6%)

4 (1.2%)

0.408

Revascularization

5 (1.4%)

5 (1.4%)

0.968

Hospitalization for heart failure

3 (0.9%)

Major adverse cardiovascular events 19 (5.5%)

2 (0.6%)

0.664

24 (6.9%)

0.382

membrane-bound metalloprotease, it can be released
from the cell membrane. The production of sNEP is
known to occur as a consequence of proteolytic cleavage
of the extracellular domain or exosomal release
dependent on A Disintegrin And Metalloprotease-17
(ADAM-17) [1, 10, 32]. In addition, NEP may exist as either a transmembrane or soluble form, and sNEP retains
its catalytic activity [1, 10, 33].
Circulating sNEP has been reported as a biomarker surrogate in patients with HF. In chronic ambulatory HF patients with at least 1 hospitalization for HF or reduced
LVEF, sNEP was positively associated with cardiovascular
mortality and morbidity [10]. In comprehensive multivariable analyses, sNEP remained to be significantly associated
with both composite endpoint and cardiovascular mortality independent of conventional clinical risk factors and
NT-proBNP. Elevated sNEP levels predicted an increased
risk of recurrent admission for HF in the same study
population with chronic HF [34]. In addition, the
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Fig. 2 Receiver operating characteristic curve according to the neprilysin level. a All-cause death and (b) the major cardiovascular events

prognostic value of sNEP has been evaluated in acute decompensated HF [11]. Admission sNEP concentration was
associated with short- and long-term outcomes in acute
HF. On the other hand, another study could not confirm
an association between sNEP levels and cardiovascular
mortality or hospitalization for HF in patients with HFpEF
[14]. In addition, sNEP levels showed no significant relationship with myocardial infarct size and 1-year adverse
outcomes in patients with ST-elevation myocardial infarction [13]. More recently, in a large community-based
cohort, the investigators reported that sNEP did not

correlate with natriuretic peptide levels and was not independently associated with adverse outcomes [35].
The present study aimed to demonstrate the prognostic value of sNEP levels in patients with CAD undergoing PCI. To the best of our knowledge, this study is the
first analysis of sNEP as a prognostic biomarker in allcomer PCI patients. In particular, most of the patients
were relatively high-risk patients with acute coronary
syndrome. Consequently, the results of this study
showed no association between sNEP levels and longterm mortality or major cardiovascular events. However,

Fig. 3 Cumulative incidence rates according to soluble neprilysin level. a All-cause death and (b) the major cardiovascular events
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Table 3 Clinical outcomes according to the tertile and quartile of the soluble neprilysin level
Log rank, P value

Neprilysin
< 56.3 pg/ml

56.3–111.4 pg/ml

> 111.4 pg/ml

(n = 228)

(n = 235)

(n = 231)

All-cause death

15 (6.5%)

13 (5.6%)

MACE

11 (4.8%)

15 (6.5%)

20 (8.7%)

0.410

17 (7.4%)

0.470
Log rank, P value

Neprilysin
< 46.8 pg/ml

46.8–76.0 pg/ml

76.0–133.9 pg/ml

(n = 173)

(n = 175)

All-cause death

11 (6.4%)

9 (5.1%)

12 (6.9%)

16 (9.2%)

0.482

MACE

8 (4.6%)

11 (6.3%)

12 (6.9%)

12 (6.9%)

0.760

(n = 173)

> 133.9 pg/ml
(n = 173)

MACE indicates major adverse cardiovascular events

in the subgroup analysis, CAD patients with reduced
LVEF seemed to show a positive association between circulating sNEP levels and mortality and MACE, while
there was no association between circulating sNEP levels
and preserved LVEF. These findings are consistent with
the results of previous studies regarding sNEP as a biomarker for long-term clinical outcomes in patients with
HFrEF and HFpEF. However, this finding may not be
conclusive because only 12.4% of patients who were included in our study presented with LVEF less than 40%,
and the subgroup analysis did not have strong statistical
power.
Table 4 Association between the neprilysin level with all-cause
death and major adverse cardiovascular events
HR (95% CI)

P value

Model 1 (univariate)

1.437 (0.810–2.552)

0.215

Model 2 (age, sex)

1.567 (0.882–2.783)

0.125

Model 3 (age, sex, smoking)

1.575 (0.887–2.798)

0.121

Model
All-cause death

Model 4 (age, sex, LVEF)

1.598 (0.898–2.842)

0.111

Model 5 (age, sex. NT-proBNP)

1.414 (0.789–2.534)

0.244

Model 6a

1.701 (0.892–3.247)

0.107

Major adverse cardiovascular events.
Model 1 (univariate)

1.307 (0.716–2.386)

0.384

Model 2 (age, sex)

1.431 (0.783–2.614)

0.244

Model 3 (age, sex, smoking)

1.431 (0.784–2.613)

0.244

Model 4 (age, sex, LVEF)

1.528 (0.834–2.798)

0.170

Model 5 (age, sex. NT-proBNP)

1.309 (0.705–2.430)

0.394

Model 6a

1.624 (0.843–3.127)

0.147

HR indicates hazard ratio, CI confidence interval, LVEF left ventricular ejection
fraction, NT-proBNP N-terminal pro-B type natriuretic peptide
a
After adjustment for age, sex, body mass index, hypertension, diabetes
mellitus, dyslipidemia, smoking, family history of coronary artery disease, prior
stroke, clinical presentation (myocardial infarction vs. angina), LVEF, NTproBNP, and estimated glomerular filtration rate

Nevertheless, the present results may be translated
meaningfully by expanding further studies in the future.
To summarize, in previous studies, sNEP levels were associated with long-term prognosis in patients with HFrEF or
acute HF, whereas they were not associated with outcomes in patients with HFpEF. In addition, the combination of a NEP inhibitor with angiotensin receptor blocker
demonstrated superior clinical outcomes in patients with
HFrEF and a greater reduction in the NT-proBNP concentration in patients with acute decompensated HF than
did an angiotensin-converting enzyme inhibitor alone,
while the combination therapy did not result in a significantly lower rate of the clinical outcome among patients
with HFpEF. On the basis of these previous results and
our results, serum sNEP levels can be used to predict the
long-term prognosis of patients with ischemic heart disease accompanied by chronic HFrEF or acute HF or CAD
patients with reduced LVEF, and further findings will support the importance of NEP inhibition in those populations concerning better clinical outcomes.
Previous studies showed that sNEP levels were lower
in HFpEF compared with controls without HFpEF, and
the lowest sNEP tertile group had the highest prevalence
of diastolic dysfunction in general population [6, 35].
The other study found that plasma NEP concentration
was lower in non-acute decompensated HF than acute
decompensated HF and higher in chronic HF than acute
decompensated HF [36]. The same study demonstrated
different patterns in distributions of immunoreactive Ntype natriuretic peptides or circulating neprilysin activity. The action mechanisms of NEP, such as interaction
between NEP and numerous vasoactive peptides or relationship between sNEP activity and concentration, have
remained unknown. Our study found that serum sNEP
levels were lower in CAD patients with reduced LVEF
compared with those with preserved LVEF. Further investigations are needed to elucidate this paradoxical
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Table 5 Association between clinical characteristics and the risk of all-cause death during follow-up analyzed by univariate and
multivariate Cox proportional hazard model
Univariate

Multivariate

HR (95% CI)

P value

HR (95% CI)

P value

Age

1.110 (1.075–1.146)

< 0.001

1.077 (1.027–1.130)

0.002

Female

1.748 (0.991–3.085)

0.054

1.133 (0.594–2.160)

0.705

Body mass index

0.917 (0.880–0.956)

< 0.001

1.037 (0.938–1.147)

0.473

Hypertension

1.885 (0.913–3.891)

0.087

1.099 (0.465–2.600)

0.830

Diabetes mellitus

1.414 (0.802–2.495)

0.232

Dyslipidemia

1.008 (0.547–1.856)

0.980

Smoking

0.487 (0.228–1.040)

0.063

1.234 (0.523–2.915)

0.631

Family history of CAD

0.527 (0.128–2.171)

0.375

Chronic kidney disease

2.472 (0.979–6.243)

0.055

0.957 (0.303–3.018)

0.940

Prior stroke

1.436 (0.644–3.200)

0.377

Acute myocardial infarction

4.320 (2.153–8.671)

< 0.001

3.191 (1.502–6.776)

0.003

Left ventricular ejection fraction

0.947 (0.929–0.965)

< 0.001

0.967 (0.942–0.994)

0.015

eGFR

0.960 (0.948–0.973)

< 0.001

0.983 (0.960–1.007)

0.173

NT-proBNP

1.000 (1.000–1.000)

< 0.001

1.000 (1.000–1.000)

0.420

Multivessel disease

1.009 (0.548–1.857)

0.978

Number of total stents

0.992 (0.764–1.290)

0.954

Mean diameter of stents

0.745 (0.363–1.528)

0.421

Total length of stents

1.006 (0.998–1.013)

0.168

Neprilysin > 76.0 pg/ml

1.437 (0.810–2.552)

0.215

1.558 (0.848–2.863)

0.153

HR indicates hazard ratio, CI confidence interval, CAD coronary artery disease, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-B-type
natriuretic peptide

Fig. 4 Comparison of outcomes between soluble neprilysin level higher and lower group according to subgroups. a All-cause death and (b) the
major cardiovascular events
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Fig. 5 Longitudinal associations of soluble neprilysin and risk of outcomes according to LVEF after multivariable adjustment. a All-cause death
and (b) the major adverse cardiovascular events. Solid purple lines represent the calculated log relative hazard in patients with left ventricular
ejection fraction less than 40, and the dashed yellow line represents the log relative hazard for patients with left ventricular ejection fraction
equal to or greater than 40. Shaded gray areas represent 95% confidence intervals. LVEF = left ventricular ejection fraction

finding of low concentration and potential prognostic
values in patients with reduced LVEF. Furthermore, patients with higher neprilysin level group were younger
than lower group. Similar to this study, there was a
study that age was negatively associated with level of
neprilysin [34]. The mechanism of the negative correlation between age and neprilysin have remained unknown, and further evaluation is needed.
The present study has some limitations. First, we could
not assess the biological activity of serum NEP. Therefore,
we could not analyze the relationship between serum
levels and biological activity and could not adjust these
relationships. Second, we collected a blood sample only
once per patient at the time of coronary angiography and
could not evaluate the changes in sNEP levels. We cannot
exclude that changes in sNEP levels are related to longterm clinical outcomes in ischemic heart disease. Third,
the blood samples were stored for 1 ~ 2 years prior to analysis because the ELISAs were performed once after all
patients were enrolled. Therefore, some unexpected alterations might have occurred, and these changes could
affect the results. Finally, the present study included
patients with CAD undergoing PCI, and the results of our
study may not be directly applicable to patients with other
categories of the disease entity.

Conclusions
Serum sNEP levels are not associated with the risk of
all-cause death and cardiovascular events in patients
with CAD undergoing PCI. Among patients with LVEF

less than 40%, increased sNEP levels seem to be associated with a higher risk of all-cause death. The prognostic
value of sNEP levels may be different depending on
whether LVEF is preserved or reduced in ischemic heart
disease. Further large-scale studies are needed to verify
the results of the present study, and large clinical trials
will translate these results into clinical practice to determine whether a NEP inhibitor improves the clinical outcomes in ischemic heart disease with or without
decreased left ventricular systolic function.
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